Aromatase inhibitors (AIs) have been utilized for a number of estrogen-modulated conditions,
including hormone-sensitive breast cancer, endometriosis and ovulation induction.
Some borderline ovarian tumors (BOT) are estrogen-receptor positive, and case reports
suggest the use of AIs in the prevention of recurrent serous BOT. We present a case
of progression from mucinous cystadenoma to mucinous BOT after two prior cystectomies
in whom an AI was used and the patient is now 2 years without recurrent disease.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Pediatric and Adolescent GynecologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
